Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

GLP-1s are clinically impressive — but still too pricey. A new CVS Health white paper found that while GLP-1 drugs cut hospitalizations and cardiac events, pharmacy costs still outpace medical savings at today's prices. CVS says a $350/month price point would flip the equation and push more employers to offer broader coverage.
GLP-1 drugs are delivering real clinical wins — fewer hospitalizations, lower cardiac risk, better health outcomes — but the price tag is still a dealbreaker for many employers. A new CVS Health white paper, released at the HLTH 2026 conference in Las Vegas, analyzed three years of Aetna claims data and found that while GLP-1 users racked up $9,400 less in medical spending per person, pharmacy costs shot up by $13,300 — leaving plan sponsors $3,900 in the hole per patient.
CVS CMO Dr. Amy Compton-Phillips is using the findings to publicly pressure drugmakers like Eli Lilly and Novo Nordisk to lower prices. She pointed out that both companies already supply GLP-1s to Medicare at ~$245/month — and are still profitable — raising questions about why employers pay $617–$766/month for the same drugs. The report also flags a structural challenge: employer turnover means companies often foot the bill for GLP-1s without ever seeing the long-term savings.
By the Numbers:
Why it matters: With employer GLP-1 coverage shrinking and costs still climbing, this study puts a concrete number on what "affordable" looks like — and turns up the heat on pharma to price these blockbuster drugs in a way that keeps more patients on them long-term.